From HIPAA to doctor-patient confidentiality, the U.S. healthcare system is replete with provisions designed to ensure patient privacy. Most people are surprised, then, to hear that patients in the United States do not legally own nearly any of their health data: data as diverse as health and medical records, labs, x-rays, genetic information, and even physical specimens such as tissue and blood removed during a procedure.
Providing patients with agency over their health data is necessary for elevating patients as partners in their own health management—as individuals capable of making genuinely informed and even lifesaving decisions regarding treatment options.
The next administration should pursue a two-pronged approach to help do just that. First, the administration should launch a coordinated and comprehensive patient-education and public- awareness campaign. This campaign should designate patient data and tissue rights as a national public-health priority. Second, the administration should expand provisions in the Cures 2.0 Act to ensure that healthcare providers are equally invested in and educated about these critical patient issues. These steps will accelerate a needed shift within the U.S. healthcare system towards a culture that embraces patients as active participants in their own care, improve health- data literacy across diverse patient populations, and build momentum for broader legislative change and around complex and challenging issues of health information and privacy.
While the U.S. government grapples with the definition of the bioeconomy and what sectors it does and does not contain, another definitional issue needs to be addressed: What does sustainability mean in a bioeconomy?
Federal clearinghouses should incorporate open science practices into their standards and procedures used to identify evidence-based social programs eligible for federal funding.
To better address security and sustainability of open source software, the United States should establish a Digital Technology Fund through multi-stakeholder participation.
Building on existing data and privacy efforts, the White House and federal science agencies should collaborate to develop and implement clear standards for research data privacy across the data management and sharing life cycle.